Company Analysis
Sign in

Tenaya Therapeutics, Inc. (TNYA)

Nasdaq: TNYA · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2021
Full chart Alerts Compare
Grade4.8
◀ Past 3.7● Present 4.4▶ Future 5.9
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

14 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tenaya Therapeutics, Inc.’s names, not what it holds today.

Patents granted
14
14 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 5 in 2024 and 3 in 2023
Applications published
35
8 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Biotechnology5
Organic fine chemistry3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Tenaya Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
34 published
Tenaya Therapeutics, Inc. its own name
US, as the owner printed on each patent
14 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 25, 202512,478,691Gene therapy vectors for treating heart diseasePharmaceuticalsTenaya Therapeutics, Inc.
May 27, 202512,312,345Fluoroalkyl-oxadiazoles and uses thereofOrganic fine chemistryTenaya Therapeutics, Inc.
Jan 21, 202512,201,617HDAC6 inhibitors for treatment of metabolic disease and HFpEFPharmaceuticalsTenaya Therapeutics, Inc.
Dec 17, 202412,168,778Cardiac cell reprogramming with myocardin and ASCL1BiotechnologyTenaya Therapeutics, Inc.
Nov 26, 202412,151,001Optimized expression cassettes for gene therapyBiotechnologyTenaya Therapeutics, Inc.
Oct 1, 202412,104,165Adeno-associated virus with engineered capsidBiotechnologyTenaya Therapeutics, Inc.
Mar 12, 202411,926,622Fluoroalkyl-oxadiazoles and uses thereofOrganic fine chemistryTenaya Therapeutics, Inc.
Feb 27, 202411,913,012Cardiac cell reprogramming with myocardin and ASCL1BiotechnologyTenaya Therapeutics, Inc.
Oct 10, 202311,781,156Plakophillin-2 gene therapy methods and compositionsPharmaceuticalsTenaya Therapeutics, Inc.
Sep 19, 202311,759,531Gene therapy vectors for treating heart diseasePharmaceuticalsTenaya Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 13, 20252025/0346922COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTIONOrganic fine chemistryTenaya Therapeutics, Inc.
Oct 30, 20252025/0332288CARDIOPROTECTIVE HEART DISEASE THERAPIESPharmaceuticalsTenaya Therapeutics, Inc.
Aug 7, 20252025/0250585CAPSIDS FOR PLAKOPHILLIN-2 GENE THERAPYPharmaceuticalsTenaya Therapeutics, Inc.
Aug 7, 20252025/0249126PLAKOPHILLIN-2 GENE THERAPY TREATMENT METHODSPharmaceuticalsTenaya Therapeutics, Inc.
Mar 20, 20252025/0092422CARDIAC CELL REPROGRAMMING WITH MYOCARDIN AND ASCL1BiotechnologyTenaya Therapeutics, Inc.
Mar 13, 20252025/0084385ADENO-ASSOCIATED VIRUS WITH ENGINEERED CAPSIDPharmaceuticalsTenaya Therapeutics, Inc.
Feb 13, 20252025/0051799ADENO-ASSOCIATED VIRUS WITH ENGINEERED CAPSIDBiotechnologyTenaya Therapeutics, Inc.
Feb 13, 20252025/0049959OPTIMIZED EXPRESSION CASSETTES FOR GENE THERAPYBiotechnologyTenaya Therapeutics, Inc.
Sep 12, 20242024/0301021ENHANCER SEQUENCES SPECIFIC FOR CARDIAC FIBROBLASTS AND METHODS OF USE THEREOFBiotechnologyTenaya Therapeutics, Inc.
Aug 15, 20242024/0269137HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHYPharmaceuticalsTenaya Therapeutics, Inc.
What it applied for, 2024 to 2025: Biotechnology 7 · Pharmaceuticals 6 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TNYA · research, not advice